Clinical Trial

A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A single-center, open-label, fixed-sequence, self-controlled phase I clinical trial aimed at evaluating the effect of itraconazole capsules(CYP3A inhibitor) on the pharmacokinetics of HS-10506 tablets in healthy participants.
Trial Details
NCT Number NCT07535970
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Healthy Participants
Enrollment 20 participants
Start Date 2026-04-30
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-17